Antibodies to SARS coronavirus
US7728110B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 21, 2007 |
| Grant date | Jun 1, 2010 |
| Priority date | — |
| Expiry date | Nov 11, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.